Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial [0.03%]
关于IDH2突变复发或难治的急性髓系白血病或骨髓增生异常综合征患者使用恩西地平与维奈克拉联合治疗的Ib/II期、多中心单组试验（ENAVEN-AML）：研究结果
Guillaume Richard-Carpentier,Gopila Gupta,Charina Koraksic et al.
Guillaume Richard-Carpentier et al.
Background: Enasidenib, a mutant IDH2 inhibitor, is used to treat IDH2-mutated acute myeloid leukaemia (AML). Preclinical studies have demonstrated synergy between enasidenib and venetoclax, a BCL2 inhibitor, in IDH2-muta...
Baptiste Le Calvez,Stéphanie Mathis,Pierre Lemaire et al.
Baptiste Le Calvez et al.
Incidence, mortality, and survival associated with acute leukaemia subtypes by age group in China: a population-based cancer registry analysis and cohort study [0.03%]
中国急性白血病亚型的年龄别发病、死亡及生存结局分析：基于癌症登记数据的队列研究
Wei Yin,Xiaoyu Yan,Jiaoyang Cai et al.
Wei Yin et al.
Background: Acute leukaemia represents a crucial health challenge. However, nationwide data delineating the incidence of acute leukaemia subtypes, as well as mortality and survival outcomes, remain scarce in China. We aim...
GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial [0.03%]
针对复发/难治多发性骨髓瘤患者GRPC5D靶点的CAR-T细胞疗法（CT071）：一项首次在人体内开展的第一阶段单中心单臂试验
Lina Jin,Sinan Gu,Qianqi Ruan et al.
Lina Jin et al.
Background: Relapsed or refractory multiple myeloma remains incurable. CT071 is a fully human, autologous, chimeric antigen receptor (CAR) T-cell therapy directed against G protein-coupled receptor class C group 5 member ...
Establishing a sustainable academic point-of-care network for CAR T-cell therapy [0.03%]
建立可持续的学术基于点护理网络以进行CAR-T细胞治疗
Eulàlia Olesti,Mireia Bachiller,Aina Oliver-Caldés et al.
Eulàlia Olesti et al.
Indicators of inequity in research and funding for sickle cell disease, cystic fibrosis and haemophilia: a descriptive comparative study [0.03%]
一项描述性研究：镰状细胞病、囊性纤维化和血友病研究与资助中的不平等指标比较研究
Rutendo Muzambi,Alex Bottle,Daniel Dexter et al.
Rutendo Muzambi et al.
Background: Sickle cell disease, one of the most common genetic conditions in the UK, is often considered a neglected disorder, but rigorous quantitative evidence to support this view is scarce. Comparative research of mu...
The Lancet Haematology
The Lancet Haematology
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study [0.03%]
Rituximab、苯达莫司汀和阿糖胞苷后继以Venetoclax治疗高风险套细胞淋巴瘤老年患者：一项多中心单臂二期研究（FIL_V-RBAC）
Carlo Visco,Valentina Tabanelli,Maria Vittoria Sacchi et al.
Carlo Visco et al.
Background: Bendamustine and rituximab combined with intermediate-dose cytarabine (RBAC) is one of the standard initial treatments for older, fit patients with mantle cell lymphoma. We aimed to investigate whether the add...